InflaRx N.V. announced a private placement of 500,0000 common shares at a price of $5 per share for the gross proceeds of $2.5 million in a round of funding on December 21, 2022. The transaction will include participation from returning investor, Staidson (Beijing) BioPharmaceuticals Co., Ltd. The share purchase agreement also includes an option pursuant to which Staidson (Beijing) BioPharmaceuticals Co., Ltd may purchase additional ordinary shares, at company?s discretion, for an aggregate amount of an additional $7.5 million.